Ideaya Biosciences Inc.

Ideaya Biosciences Inc. is a precision medicine oncology company that discovers and develops targeted therapeutics for patient populations identified through molecular diagnostics. Its pipeline features IDE196, a protein kinase C inhibitor in Phase 2/3 clinical trials for cancers with GNAQ or GNA11 mutations; IDE397, a methionine adenosyltransferase 2a inhibitor in Phase 2 for solid tumors with MTAP deletions like non-small cell lung cancer and urothelial cancer; IDE849, a DLL3 antibody drug conjugate in Phase 1 for small cell lung cancer and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor in Phase 1 for high microsatellite instability tumors; IDE161, a poly ADP-ribose glycohydrolase inhibitor in Phase 1/2 for homologous recombination deficiency tumors; and IDE705, a Poly Theta Helicase inhibitor in Phase 1 for BRCA-mutated tumors. The company also advances preclinical programs such as IDE892, an MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 bispecific antibody drug conjugate; and IDE251, a KAT6/7 inhibitor, alongside research platforms like DECIPHER for synthetic lethality and INQUIRE for drug discovery enhancement. Ideaya Biosciences Inc. maintains strategic alliances with partners including GlaxoSmithKline, Pfizer, Gilead Sciences, Merck, and others. Incorporated in 2015 and headquartered in South San Francisco, California, it plays a key role in advancing precision oncology therapies.